Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events among persons with type 2 diabetes. The effect of an exendin-based GLP-1 receptor agonist, efpeglenatide, on cardiovascular and renal outcomes in patients with type 2 diabetes who are also at high risk for adverse cardiovascular events is uncertain. METHODS: of body-surface area) plus at least one other cardiovascular risk factor. Participants were randomly assigned in a 1:1:1 ratio to receive weekly subcutaneous injections of efpeglenatide at a dose of 4 or 6 mg or placebo. Randomization was stratified according to use of sodium-glucose cotransporter 2 inhibitors. The primary outcome was the first major adverse cardiovascular event (MACE; a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular or undetermined causes). RESULTS: A total of 4076 participants were enrolled; 2717 were assigned to receive efpeglenatide and 1359 to receive placebo. During a median follow-up of 1.81 years, an incident MACE occurred in 189 participants (7.0%) assigned to receive efpeglenatide (3.9 events per 100 person-years) and 125 participants (9.2%) assigned to receive placebo (5.3 events per 100 person-years) (hazard ratio, 0.73; 95% confidence interval [CI], 0.58 to 0.92; P<0.001 for noninferiority; P = 0.007 for superiority). A composite renal outcome event (a decrease in kidney function or macroalbuminuria) occurred in 353 participants (13.0%) assigned to receive efpeglenatide and in 250 participants (18.4%) assigned to receive placebo (hazard ratio, 0.68; 95% CI, 0.57 to 0.79; P<0.001). Diarrhea, constipation, nausea, vomiting, or bloating occurred more frequently with efpeglenatide than with placebo. CONCLUSIONS: In this trial involving participants with type 2 diabetes who had either a history of cardiovascular disease or current kidney disease plus at least one other cardiovascular risk factor, the risk of cardiovascular events was lower among those who received weekly subcutaneous injections of efpeglenatide at a dose of 4 or 6 mg than among those who received placebo. (Funded by Sanofi; AMPLITUDE-O ClinicalTrials.gov number, NCT03496298.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The effects of semaglutide on albuminuria and eGFR observed in the present STEP analysis are consistent with post hoc analyses of other GLP-1RA clinical trials.”
From Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: exploratory analysis from the STEP 1, 2, and 3 trials (2023) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most GLP-1 RAs had a neutral effect on risk of HF hospitalization in the placebo-controlled RCTs assessing CV safety of glucose-lowering medications in patients with T2DM with or at high risk of ASCVD, despite increasing heart rate by 3-5 b.p.m. 70,72,158- 163,544”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [163]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging data suggest that use of both classes of drugs will provide an additive cardiovascular and kidney outcomes benefit;”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [270]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Over a median follow-up of 1.8 years, efpeglenatide therapy reduced the risk of incident major adverse cardiovascular events by 27% and of a composite renal outcome event by 32%.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [214]
The cited source says what the claim attributes to it.
In the citing paper
“Some GLP-1RAs [albiglutide, efpeglenatide, dulaglutide, liraglutide and once-weekly (OW) semaglutide] reduce the risk of major adverse CV events (MACE) in people with T2D with established CVD or at high risk of CVD [6][7][8][9][10].”
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440
Self-citationKristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Self-citationType 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people
Shah, A. D., Langenberg, C., Rapsomaniki, E., Denaxas, S., Pujades-Rodriguez, M., Gale, C. P., Deanfield, J., Smeeth, L., Timmis, A., & Hemingway, H. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70219-0 · Cited by 1,225
Association of cardiometabolic multimorbidity with mortality
Di Angelantonio, E., Kaptoge, S., Wormser, D., Willeit, P., Butterworth, A. S., Bansal, N., O’Keeffe, L. M., Gao, P., Wood, A. M., Burgess, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.7008 · Cited by 1,155
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes
Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008121270 · Cited by 965
Matsushita, K., Coresh, J., Sang, Y., Chalmers, J., Fox, C., Guallar, E., Jafar, T., Jassal, S. K., Landman, G. W. D., Muntner, P., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00040-6 · Cited by 903
The Global Epidemiology of Diabetes and Kidney Disease
Koye, D. N., Magliano, D. J., Nelson, R. G., & Pavkov, M. E. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.10.011 · Cited by 686
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638
Self-citationLaiteerapong, N., Ham, S. A., Gao, Y., Moffet, H. H., Liu, J. Y., Huang, E. S., & Karter, A. J. (2019) · Diabetes Care · doi:10.2337/dc17-1144 · Cited by 574
Cited by
Items 301–400 of 873
Anti-atherosclerotic effect of incretin receptor agonists
Wang, X., Yang, X., Qi, X., Fan, G., Zhou, L., Peng, Z., & Yang, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1463547 · Cited by 22
Tang, H., Zhang, B., Lu, Y., Donahoo, W. T., Ospina, N. S., Kotecha, P., Lu, Y., Tong, J., Smith, S. M., Rosenberg, E. I., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16147 · Cited by 20
Tommerdahl, K. L., Kendrick, J., & Bjornstad, P. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00020122 · Cited by 19
Kalayci, A., Januzzi, J. L., Mitsunami, M., Tanboga, I. H., Karabay, C. Y., & Gibson, C. M. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf037 · Cited by 18
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01036-y · Cited by 22
Rivera, F. B., Chin, M. N. C., Pine, P. L. S., Ruyeras, M. M. J., Galang, D. J. C., Gandionco, K. M., Morales, B. L. F. D., Climaco, Z. M. V., Bantayan, N. R. B., Magalong, J. V., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2442027 · Cited by 19
Diabetes and cardiovascular disease in older adults
Bilal, A., & Pratley, R. E. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15259 · Cited by 21
Self-citationThe Close Link Between Obesity and Cardiovascular Disease
Lee, H., Rhee, T., Choi, J. M., Choi, S., & Kim, D. W. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.10.005 · Cited by 18
Chang, Y., Chi, K., Song, J., & Lin, H.-M. (2025) · The Spine Journal · doi:10.1016/j.spinee.2025.07.010 · Cited by 18
A review of the evidence on cardiovascular outcomes from obesity treatment
Wahab, R. A., & le Roux, C. W. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100071 · Cited by 21
Obesity-Related Kidney Disease: A Growing Threat to Renal Health
León-Román, J. C., López-Martínez, M., Esteves, A., Ciudin, A., Núñez-Delgado, S., Álvarez, T., Lecube, A., Rico-Fontalvo, J. E., & Soler, M. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146641 · Cited by 19
Shokravi, A., Seth, J., Lu, N., & Mancini, G. B. J. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00248-2 · Cited by 17
Cardiorenal interactions in heart failure: insights from recent therapeutic advances
Damman, K., & Testani, J. M. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad096 · Cited by 17
Lyons, S. A., & Beaudry, J. L. (2023) · Endocrinology · doi:10.1210/endocr/bqad153 · Cited by 19
Karagiannis, T., Τσάπας, Α., Bekiari, E., Toulis, K. A., & Nauck, M. A. (2024) · Diabetes Care · doi:10.2337/dc23-0925 · Cited by 17
Incretin and glucagon receptor polypharmacology in chronic kidney disease
McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 17
Khan, M. S., & Lea, J. P. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03652-5 · Cited by 19
Shah, M. U., Roebuck, A., Srinivasan, B., Ward, J. K., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499681 · Cited by 23
Lin, Y., Wu, J., Lee, M.-C., Su, C.-Y., Toh, H. S., Chang, W., Chen, S.-Y., Kuo, F., Tang, H., & Liao, C. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae093 · Cited by 20
Seetharaman, R., Pawar, S. R., & Advani, M. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15100 · Cited by 17
The potential of glucagon-like peptide-1 receptor agonists in heart failure
Kreiner, F. F., Hovingh, G. K., & von Scholten, B. J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.983961 · Cited by 17
Husain, M., Consoli, A., De Remigis, A., Pettersson Meyer, A. S., Rasmussen, S., & Bain, S. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01489-6 · Cited by 16
Pugliese, N. R., Paneni, F., Tricò, D., Bacca, A. V., De Biase, N., Dalpiaz, H., Mengozzi, A., Virdis, A., Ghiadoni, L., Taddei, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02778-6 · Cited by 16
“…GLP-1 RA therapy reduces the relative risk of hospital admission for HF by 11% (hazard ratio [HR] 0.89; 95% confidence interval [CI] 0.82–0.98) [35], confirming positive findings initially observed in the 4076 patients with type 2 diabetes at high CVD risk included in the AMPLITUDE-O [36] trial.”
InfluentialMannucci, E., & Silverii, G. A. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15226 · Cited by 16
Hasebe, M., Su, C., Keidai, Y., Minamino, H., Yabe, D., Inagaki, N., & Yoshiji, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70121 · Cited by 16
Katamine, M., Minami, Y., & Ako, J. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22044 · Cited by 19
Hung, C., Zeng, B., Hsu, C.-W., Chen, P., Sun, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003450 · Cited by 20
Júlíusdóttir, Y. K., Halili, A., Coronel, R., Folke, F., Torp-Pedersen, C. T., Gislason, G., & Eroglu, T. E. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad033 · Cited by 17
Liraglutide alleviates experimental diabetic cardiomyopathy in a PDH-dependent manner
Chan, J. S. F., Greenwell, A. A., Saed, C. T., Stenlund, M. J., Mangra-Bala, I. A., Dakhili, S. A. T., Yang, K., Ferrari, S. R., Eaton, F., Gopal, K., et al. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0032 · Cited by 17
Longato, E., Camillo, B. D., Sparacino, G., Tramontan, L., Avogaro, A., & Fadini, G. P. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01414-3 · Cited by 17
Williams, D. M., Atkinson, M., & Evans, M. (2023) · Stroke · doi:10.1161/strokeaha.122.042109 · Cited by 18
Sohn, M., Frías, J. P., & Lim, S. K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15251 · Cited by 17
Moreno, Ó., Reyes‐García, R., Pardo, I. M., López-Martínez, M., & Soler, M. J. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae039 · Cited by 15
A New Era in Diabetic Kidney Disease Treatment: The Four Pillars and Strategies to Build Beyond
Han, S., & Kim, S. (2024) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2024.22.2.21 · Cited by 15
Ferrari, F., Scheffel, R. S., Martins, V. M., Santos, R. D., & Stein, R. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00515-4 · Cited by 18
Kobayashi, K., Toyoda, M., Hatori, N., Sakai, H., Furuki, T., Chin, K., Kimura, M., Saito, N., Kanaoka, T., Aoyama, T., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109231 · Cited by 16
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 21
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
Schnell, O., Battelino, T., Bergenstal, R. M., Blüher, M., Böhm, M., Brosius, F. C., Carr, R. D., Ceriello, A., Forst, T. M., Giorgino, F., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01481-0 · Cited by 17
Bilal, A., Yi, F., Gonzalez, G. R., Ali, M., Im, K., Ruff, C. T., Thethi, T. K., & Pratley, R. E. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108783 · Cited by 14
Self-citationØstergaard, S. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2601113 · Cited by 16
Aroda, V. R., Frías, J. P., Ji, L., Niemoeller, E., Nguyên‐Pascal, M., Denkel, K., Espinasse, M., Guo, H., Baek, S. J., Choi, J., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15079 · Cited by 14
Wei, H., Ye, L., Li, M., Huang, S., & Mo, Z. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf075 · Cited by 16
Siniukovich, A., Travlos, C. K., Freedman, S., Mavrakanas, T. A., & Gariani, K. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01831-4 · Cited by 14
Targeting Sarcopenia in CKD: The Emerging Role of GLP-1 Receptor Agonists
Llinares-Arvelo, V., Martínez‐Alberto, C. E., González-Luis, A., Macía-Heras, M., Siverio-Morales, O., Navarro‐González, J. F., & Donate‐Correa, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168096 · Cited by 15
Cardiovascular effects of GLP-1 receptor agonism
Winquist, R. J., & Gribkoff, V. K. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2022.02.005 · Cited by 16
Precision Nephrology in Patients with Diabetes and Chronic Kidney Disease
Provenzano, M., Maritati, F., Abenavoli, C., Bini, C., Corradetti, V., Manna, G. L., & Comai, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105719 · Cited by 18
Meta‐analysis of Association between Newer Glucose‐Lowering Drugs and Risk of Parkinson's Disease
Tang, H., Lu, Y., Okun, M. S., Donahoo, W. T., Ramirez‐Zamora, A., Wang, F., Huang, Y., Chen, W., Virnig, B. A., Bian, J., et al. (2023) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13893 · Cited by 16
Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease
Alicic, R. Z., & Neumiller, J. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010201 · Cited by 16
Banerjee, M., Pal, R., Maisnam, I., & Mukhopadhyay, S. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.102943 · Cited by 14
Gomes, D., Presume, J., Gonçalves, P. D. A., Almeida, M., Mendes, M., & Ferreira, J. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07547-3 · Cited by 18
GLP-1 and the cardiovascular system
Kahles, F., Birkenfeld, A. L., & Marx, N. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194748 · Cited by 14
Podder, D., Stala, O., Miah, A., Agyapong, A., Moore, M. E., Hirani, R., Diegisser, D., Garcia, V. G., & Etienne, M. (2026) · Diabetology · doi:10.3390/diabetology7030046 · Cited by 19
New Perspectives in Management of Cardiovascular Risk Among People With Diabetes
Gami, A., Blumenthal, R. S., McGuire, D. K., Sarkar, S., & Kohli, P. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.034053 · Cited by 17
Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Case-Based Narrative Review
Javaid, A., Hariri, E. H., Özkan, B., Lang, K., Khan, S. S., Rangaswami, J., Stone, N. J., Blumenthal, R. S., & Ndumele, C. E. (2025) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2025.100089 · Cited by 15
Radakrishnan, A., Agrawal, S., Singh, N., Barbieri, A., Shaw, L. J., Gulati, M., & Lala, A. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100928 · Cited by 14
Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review
Chen, Q., Anijs, R. J. S., Verlaan, J. P. L., Scheres, L. J. J., Klok, F. A., & Cannegieter, S. C. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2546-0353 · Cited by 15
Chen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 14
Gut microbiota implication in diabetic kidney disease: mechanisms and novel therapeutic strategies
Zhang, Y., Qing, J., Saed, Y. A., & Li, Y. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2517402 · Cited by 18
Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review
Hammad, B. F., Zafar, N., Ullah, M., Faisal, S. J., Iftikhar, F., Waheed, H., Muzaffar, M. W., Ahmed, K., Ashraf, F., Zahid, K., et al. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1590530 · Cited by 14
Jha, K. K., Adhikari, R., Tasdighi, E., Osuji, N., Rajan, T., & Blaha, M. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01066-y · Cited by 13
Sagris, D., Ntaios, G., & Milionis, H. J. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-329149 · Cited by 13
Pratley, R. E., Jacob, S., Baek, S., Trautmann, M. E., Hompesch, M., Han, O., Stewart, J., Sorli, C. H., Shaunik, A., & Yoon, K.-H. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002207 · Cited by 14
Self-citationThe year in cardiovascular medicine 2021: diabetes and metabolic disorders
Cosentino, F., Bhatt, D. L., Marx, N., & Verma, S. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab876 · Cited by 13
Georgianos, P. I., Vaios, V., Roumeliotis, S. K., Leivaditis, K., Eleftheriadis, T., & Liakopoulos, V. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020223 · Cited by 15
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Seksaria, S., Dutta, B. J., Kaur, M., Gupta, G. D., Bodakhe, S. H., & Singh, A. (2023) · Current Diabetes Reviews · doi:10.2174/1573399820666230809152148 · Cited by 12
The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease
Vasco, M. A. E., Fantaye, S. H., Raghunathan, S., & Solis‐Herrera, C. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15773 · Cited by 13
Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist–based therapies
Morissette, A., & Mulvihill, E. E. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.012 · Cited by 13
Incretin-based therapy: a new horizon in diabetes management
Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 13
Wang, T., Yang, Q., Cheng, X.-Y., Ding, J.-C., & Hu, P.-F. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10438-2 · Cited by 14
Alammari, N. A., ALSHEHRI, A. S., Khalaf, A. A., Alamri, R., Alhalal, N., Sultan, M. A. A., Ogran, N., Aljohani, R., Alasmari, S. M. S., Alsharif, S. B., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16476 · Cited by 13
The Liraglutide Effects in Atrial Fibrillation (LEAF) Study
Goldberger, J. J., Mitrani, R. D., Fishman, J. E., Zaatari, G., Lowery, M. H., Baez-Garcia, C., Aguilar, V., Blandon, C., Hurwitz, B. E., Velasquez, A. H., et al. (2026) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2026.03.026 · Cited by 15
Liu, G., Zhong, X., Zheng, J., Zhang, J., Kong, W., Hu, X. F., Min, J., Xia, W., Zeng, T., & Chen, L. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01391-8 · Cited by 13
Cases, A. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.09.003 · Cited by 16
Unexplained Residual Risk In Type 2 Diabetes: How Big Is The Problem?
Neppala, S., Rajan, J., Yang, E., & DeFronzo, R. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02055-0 · Cited by 12
Obrador, G. T., Álvarez-Estévez, G., Bellorín-Font, E., Bonanno-Hidalgo, C., Clavero, R., Correa‐Rotter, R., Diná-Batlle, E., Morales, L., Orozco, R., Ortiz, F., et al. (2024) · Nefrología Latinoamericana · doi:10.24875/nefro.m24000037 · Cited by 16
Waqas, S. A., Ali, D., Afridi, M. K., Siddiqui, H. F., Nazir, A., Greene, S. J., & Khan, M. S. (2025) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2025.105981 · Cited by 11
Alqifari, S. F., Komi, O. A., Esmail, A., Alkhawami, K., Yousri, S., Muqresh, M. A., Alharbi, N., Khojah, A. A. A., Aljabri, A. M., Allahham, A., et al. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.331 · Cited by 11
Tariq, S., Ali, M. A., Iftikhar, H. M. H., Ali, M., Shah, S. Q. A., Perveen, F., & Zaman, T. (2024) · Cureus · doi:10.7759/cureus.73705 · Cited by 17
Bellos, I., Marinaki, S., Λάγιου, Π., & Benetou, V. (2024) · Biomolecules · doi:10.3390/biom15010039 · Cited by 12
Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond
Faruque, L. I., Yau, K., & Cherney, D. Z. I. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001066 · Cited by 12
Beyond Blood Sugar: A Scoping Review of GLP-1 Receptor Agonists in Cardiovascular Care
Gupta, N., Zayyad, Z. A., Bhattaram, R., Tiu, D. R., Dau, J., Guburxani, V., Kalzuna, S. D., & Shroff, A. R. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00426-4 · Cited by 12
Liraglutide suppresses ferroptosis by upregulation NRF2 in type 2 diabetic cardiomyopathy
Chen, X., Wang, T., Gao, Y., Wang, G. A., Guan, J., & Dai, H. (2025) · Peptides · doi:10.1016/j.peptides.2025.171429 · Cited by 11
Hsu, C., Zeng, B., Liang, C., Zeng, B., Hung, C., Stubbs, B., Chen, Y., Lei, W., Chen, J.-J., Chen, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178202 · Cited by 12
Chronic Coronary Artery Disease
Kittleson, M. M. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-03512 · Cited by 12
Homoródi, N., Varga, É., Szabó, Z., Sztanek, F., & Harangi, M. (2025) · Biomedicines · doi:10.3390/biomedicines13112595 · Cited by 15
Yeo, D., Jo, Y., Jeong, J., Jeong, Y. D., Woo, H. G., Son, Y., Kim, S., Rhee, S. Y., & Yon, D. K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70298 · Cited by 15
Dutta, D., Mahajan, K., Kamrul-Hasan, A. B. M., Mahajan, N., Sharma, M., & Vohra, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70391 · Cited by 11
Hasebe, M., Su, C., Kamido, H., Yabe, D., & Yoshiji, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70458 · Cited by 12
Nusca, A., Piccirillo, F., Bernardini, F., Filippis, A. D., Coletti, F., Mangiacapra, F., Ricottini, E., Melfi, R., Gallo, P., Cammalleri, V., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137261 · Cited by 14
Al‐Salameh, A., Bouzegaoui, N. E., & Saraval, M. (2022) · Annales d Endocrinologie · doi:10.1016/j.ando.2022.09.023 · Cited by 14
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
Schnell, O., Battelino, T., Bergenstal, R. M., Birkenfeld, A. L., Ceriello, A., CHENG, A. Y. Y., Davies, M. J., Edelman, S. V., Forst, T. M., Giorgino, F., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01788-6 · Cited by 13
Lee, M. M. Y., & Sattar, N. A. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15085 · Cited by 11
Self-citationNovel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease
Oikonomou, E. K., Xenou, M., Zakynthinos, G. Ε., Tsaplaris, P., Lampsas, S., Bletsa, E., Gialamas, I., Kalogeras, K. I., Goliopoulou, A., Gounaridi, M. I., et al. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230703161058 · Cited by 12
Gu, X., Jiang, S., Yang, Y., & Li, W. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01251-2 · Cited by 12
Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
Inaishi, J., & Saisho, Y. (2022) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s288846 · Cited by 14
Kobayashi, K., Toyoda, M., Hatori, N., Sakai, H., Furuki, T., Sato, K., Terauchi, Y., Tamura, K., & Kanamori, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-20313-5 · Cited by 12
Hsu, C., Hsuan, C., Liao, D., Chang, J. K.-J., Chang, A. J.-W., Hee, S., Lee, H.-L., & Teng, S. I. F. (2023) · Life · doi:10.3390/life13041024 · Cited by 14
Chan, A. T. P., & Tang, S. C. W. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.285 · Cited by 11
Metadata
- Authors
- Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., Dyal, L., & Branch, K.
- Affiliations
- University of Pisa (IT)
- From the Population Health Research Institute, Hamilton Health Sciences (H.C.G., C.R., L.H., L.D.), and McMaster University (H.C.G.) — both in Hamilton, ON, Canada; the Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (N.S.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); AdventHealth Translational Research Institute, Orlando, FL (R.P.); Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (R.D.L.); National Heart Centre Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); Sanofi, Bridgewater, NJ (N.S.K.); the Section of Metabolic Diseases and Diabetes, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy (S.D.P.); and the Division of Cardiology, University of Washington, Seattle (K.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-02
- Volume
- 385
- Issue
- 10
- Pages
- 896-907
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177365549
- Cited by
- 829
- References
- 29
- Citations by year
- 2026: 150 · 2025: 187 · 2024: 159 · 2023: 149 · 2022: 136 · 2021: 47
- FWCI
- 91.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- efpeglenatide, type 2 diabetes, GLP-1 receptor agonists, exendin-4, major adverse cardiovascular events, cardiovascular risk, renal outcomes, renal function decline, macroalbuminuria, SGLT2 inhibitors, gastrointestinal adverse effects, non-inferiority, cardiovascular disease history, kidney disease, cardiovascular risk factors, myocardial infarction
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Heart Disease Risk Factors, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Kidney Diseases, Male, Middle Aged, Proline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
